Key Development
On August 17, 2026, biopharmaceutical major AstraZeneca (LSE/STO/Nasdaq: AZN) reported top-line results from three pivotal Phase 3 clinical trials in non-small cell lung cancer (NSCLC).
The readouts delivered a dual regulatory milestone for targeted precision therapies—Enhertu® and the Orpathys®–Tagrisso® combination—balanced against the Phase 3 trial failure of its investigational PD-1/CTLA-4 bispecific antibody, volrustomig.
Clinical Performance Across Phase 3 Studies:
-
Destiny-Lung04 Trial (Enhertu® – Partnered with Daiichi Sankyo):
-
Outcome: HER2-directed antibody-drug conjugate (ADC) Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard-of-care Keytruda® (pembrolizumab) plus platinum chemotherapy.
-
Cohort: First-line (1L) patients with unresectable, locally advanced or metastatic HER2-mutant nonsquamous NSCLC.
-
-
Saffron Phase 3 Trial (Orpathys® + Tagrisso® – Partnered with HUTCHMED):
-
Outcome: The all-oral targeted combination of oral c-MET inhibitor Orpathys® (savolitinib) plus third-generation EGFR-TKI Tagrisso® (osimertinib) demonstrated superior efficacy over platinum-based doublet chemotherapy across both primary endpoints: PFS and overall survival (OS).
-
Cohort: Patients with EGFR-mutated NSCLC harboring MET amplification following disease progression on first-line Tagrisso®.
-
-
Volrustomig Phase 3 Trial Failure (Anti-PD-1/CTLA-4 Bispecific):
-
Outcome: Volrustomig failed to demonstrate superior efficacy over standard-of-care Keytruda® plus chemotherapy in first-line NSCLC patients presenting tumor PD-L1 expression below 50% ($<50\%$).
-
Why It Matters
-
Accelerating Enhertu® into First-Line HER2-Mutant NSCLC: HER2-activating mutations occur in approximately $2\% – 4\%$ of NSCLC cases, frequently affecting younger patient demographics with aggressive disease courses. Following its initial FDA accelerated approval in previously treated cohorts (2022), Destiny-Lung04 establishes Enhertu as a targeted frontline therapeutic option outperforming standard chemo-immunotherapy.
-
Targeting Resistance Mechanisms in EGFR-Mutated NSCLC: EGFR mutations occur in $10\% – 15\%$ of Western NSCLC patients and $30\% – 40\%$ of Asian cohorts. Approximately one-third of these patients develop secondary MET gene amplification following first-line Tagrisso® treatment. The Orpathys + Tagrisso regimen establishes a biomarker-directed, all-oral standard to overcome MET-driven resistance globally, supporting a planned U.S. NDA filing.
-
Clinical Hurdles in Broad Immuno-Oncology Settings: The failure of volrustomig underscores the difficulty of displacing pembrolizumab-based regimens in broad, biomarker-unselected cohorts (PD-L1 $<50\%$), focusing attention on AstraZeneca’s next-generation oncology candidates, including rilvegostomig (PD-1/TIGIT bispecific) and Datroway (datopotamab deruxtecan / TROP2 ADC in the Phase 3 Avanzar trial).
Healthcare Insight Analysis
From the perspective of Healthcare Insight, AstraZeneca’s August 17, 2026 trial readouts highlight Niche Precision Oncology vs. Broad IO Headwinds.
AstraZeneca maintains an enterprise objective to provide therapeutic regimens for over 50% of global lung cancer patients by 2030.
These trial data provide two key portfolio takeaways:
-
Clinical Efficacy in Biomarker-Selected Populations: Both Enhertu (HER2 mutations) and Orpathys (MET amplification defined by IHC3+ in $\ge 90\%$ of cells or FISH 10+) demonstrate that specific molecular patient stratification yields substantial PFS and OS benefits ($66\% – 68\%$ risk reductions documented across Sachi and Saffron frameworks).
-
Translational Complexity of Dual Immune Checkpoint Blockade: Volrustomig’s outcome indicates that unselected dual PD-1/CTLA-4 checkpoint inhibition does not consistently overcome standard-of-care chemo-immunotherapy without more refined patient stratification.
Market Implications
-
Global Regulatory Submissions for Enhertu & Orpathys: AstraZeneca, Daiichi Sankyo, and HUTCHMED will submit clinical dossiers to the U.S. FDA, EMA, and national regulatory bodies during H2 2026 to expand 1L Enhertu labeling and secure initial Western approvals for Orpathys.
-
Expanding Diagnostic Demand for HER2 and MET Testing: Molecular pathology laboratories will expand NGS sequencing and FISH/IHC testing protocols to identify HER2 mutations and MET amplification post-EGFR TKI progression.
-
Elevated Valuation Focus on TROP2 ADC Avanzar Readouts: Market analysts will monitor upcoming Phase 3 data for Datroway (datopotamab deruxtecan) in frontline NSCLC as the next major clinical milestone for AstraZeneca’s thoracic portfolio.
Phase 3 Clinical Study Matrix: AstraZeneca NSCLC Portfolio (August 17, 2026)
| Asset / Regimen | Clinical Trial Identifier | Targeted NSCLC Patient Cohort | Clinical Outcome & Regulatory Status |
| Enhertu® (T-DXd) | Daiichi Sankyo | Phase 3 Destiny-Lung04 | 1L HER2-mutant nonsquamous NSCLC | MET: Statistically significant PFS improvement vs. Keytruda + Chemo. |
| Orpathys® + Tagrisso® | HUTCHMED | Phase 3 Saffron | EGFR-mutant / MET-amplified (Post-Tagrisso) | MET: Statistically superior PFS and OS vs. platinum chemotherapy. |
| Volrustomig (PD-1/CTLA-4 bispecific) | Phase 3 First-Line | 1L NSCLC with tumor PD-L1 $<50\%$ | FAILED: Did not demonstrate superiority over Keytruda + Chem |